XBI241227P87500
- 0.04
- -0.09-69.23%
SPDR S&P Biotech ETF Newsroom
Assembly Bio Spikes After Early-stage Data for Gilead-partnered Hep B Therapy
Looking Into AbbVie's Recent Short Interest
$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
Spotlight on Amgen: Analyzing the Surge in Options Activity
SPDR S&P Biotech ETF Declares Quarterly Distribution of $0.0027
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
SPDR S&P Biotech ETF To Go Ex-Dividend On December 23rd, 2024 With 0.00269 USD Dividend Per Share
Sarepta Awarded $115.2M in Vyondys 53 Patent Case: Report
Pfizer Gains FDA Approval for Colorectal-Cancer Treatment
What's Going On With Amgen Stock On Friday?
Needham Reiterates Hold on Neurocrine Biosciencesto Hold
Neurocrine Biosciences Analyst Ratings
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
Why Is Novo Nordisk Crashing After Data for Next-gen Weight Loss Drug?
Amgen Shares Are Trading Higher. Weight-loss Related Stocks Are up on Friday Following Weaker-than-expected Data From Competitor Lilly.
Goldman Sachs Initiates Coverage On Vaxcyte With Buy Rating, Announces Price Target of $135